Trials / Completed
CompletedNCT00698893
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate the Safety of GSK Biologicals' Candidate gD Vaccine, With or Without 3D MPL
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and reactogenicity of candidate gD vaccine, with or without MPL, in HSV-seropositive subjects. The immune response elicited in these subjects will also be evaluated.
Detailed description
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes simplex candidate (gD) vaccine GSK208141 | Intramuscular injection, 2 doses, 2 different formulations (with and without MPL) |
Timeline
- Start date
- 1992-05-01
- Primary completion
- 1992-07-01
- Completion
- 1992-07-01
- First posted
- 2008-06-17
- Last updated
- 2017-06-02
Source: ClinicalTrials.gov record NCT00698893. Inclusion in this directory is not an endorsement.